In patients with HER2-positive gastric cancer, the addition of trastuzumab may be considered as the randomised controlled ToGa-trial showed that this prolonged survival in advanced gastric cancer as compared to systemic chemotherapy alone [13]. The gene discussed is ERBB2; the disease is gastric cancer.